BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 11547215)

  • 1. Therapeutic perspectives for type 2 diabetes mellitus: molecular and clinical insights.
    Mauvais-Jarvis F; Andreelli F; Hanaire-Broutin H; Charbonnel B; Girard J
    Diabetes Metab; 2001 Sep; 27(4 Pt 1):415-23. PubMed ID: 11547215
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oral antidiabetic agents: current role in type 2 diabetes mellitus.
    Krentz AJ; Bailey CJ
    Drugs; 2005; 65(3):385-411. PubMed ID: 15669880
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The pathophysiologic basis of efficacy and clinical experience with the new oral antidiabetic agents.
    Rosak C
    J Diabetes Complications; 2002; 16(1):123-32. PubMed ID: 11872380
    [TBL] [Abstract][Full Text] [Related]  

  • 4. How to fight obesity with antidiabetic drugs: targeting gut or kidney?
    Baretić M; Troskot R
    Minerva Endocrinol; 2015 Mar; 40(1):71-83. PubMed ID: 25366984
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Newly approved and promising antidiabetic agents.
    Combettes M; Kargar C
    Therapie; 2007; 62(4):293-310. PubMed ID: 17983555
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Type 2 diabetes mellitus: Which place for thiazolidinediones in the therapeutic strategy?].
    Halimi S
    Diabetes Metab; 2001 Apr; 27(2 Pt 2):287-93. PubMed ID: 11452223
    [TBL] [Abstract][Full Text] [Related]  

  • 7. beta-cell failure in diabetes and preservation by clinical treatment.
    Wajchenberg BL
    Endocr Rev; 2007 Apr; 28(2):187-218. PubMed ID: 17353295
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Drug treatment of type 2 diabetes].
    Tielmans A; Laloi-Michelin M; Coupaye M; Virally M; Meas T; Guillausseau PJ
    Presse Med; 2007 Feb; 36(2 Pt 2):269-78. PubMed ID: 17258675
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The entero-insular axis: implications for human metabolism.
    Ranganath LR
    Clin Chem Lab Med; 2008; 46(1):43-56. PubMed ID: 18020966
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Role of insulin secretagogues in the treatment of type 2 diabetes].
    Radermecker RP
    Rev Med Liege; 2005; 60(5-6):402-8. PubMed ID: 16035301
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Thiazolidinediones in type 2 diabetes. Role of peroxisome proliferator-activated receptor gamma (PPARgamma)].
    Dubois M; Vantyghem MC; Schoonjans K; Pattou F
    Ann Endocrinol (Paris); 2002 Dec; 63(6 Pt 1):511-23. PubMed ID: 12527853
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Mechanisms of action of thiazolidinediones].
    Girard J
    Diabetes Metab; 2001 Apr; 27(2 Pt 2):271-8. PubMed ID: 11452221
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Promising new approaches.
    Reasner CA
    Diabetes Obes Metab; 1999 May; 1 Suppl 1():S41-8. PubMed ID: 11220287
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Limitations of insulin-dependent drugs in the treatment of type 2 diabetes mellitus].
    Valerón PF; de Pablos-Velasco PL
    Med Clin (Barc); 2013 Sep; 141 Suppl 2():20-5. PubMed ID: 24444520
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Troglitazone: a review of its use in the management of type 2 diabetes mellitus.
    Plosker GL; Faulds D
    Drugs; 1999 Mar; 57(3):409-38. PubMed ID: 10193691
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Second line therapy: type 2 diabetic subjects failing on metformin GLP-1/DPP-IV inhibitors versus sulphonylurea/insulin: for GLP-1/DPP-IV inhibitors.
    Kumar A
    Diabetes Metab Res Rev; 2012 Dec; 28 Suppl 2():21-5. PubMed ID: 23280862
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oral antidiabetic drugs: an overview.
    Melander A
    Diabet Med; 1996 Sep; 13(9 Suppl 6):S143-7. PubMed ID: 8894498
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Current views on the mechanism of action of thiazolidinedione insulin sensitizers.
    Goldstein BJ
    Diabetes Technol Ther; 1999; 1(3):267-75. PubMed ID: 11475273
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pathophysiology of type 2 diabetes: rationale for different oral antidiabetic treatment strategies.
    Giorgino F; Laviola L; Leonardini A
    Diabetes Res Clin Pract; 2005 Jun; 68 Suppl1():S22-9. PubMed ID: 15955371
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New drugs for type 2 diabetes mellitus: what is their place in therapy?
    Krentz AJ; Patel MB; Bailey CJ
    Drugs; 2008; 68(15):2131-62. PubMed ID: 18840004
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.